CFP ENERGY (UK) LTD.

Financial Health Assessment: CFP Energy (UK) Ltd.

1. Financial Health Score: C-

Explanation: CFP Energy (UK) Ltd. is exhibiting severe symptoms of acute financial distress following a massive operational loss in FY2025, which aggressively eroded its equity base. However, the condition is stabilized by a critical, post-year-end financial "blood transfusion" of £10 million from its parent company. Without this parental life support, the prognosis would be critical; with it, the patient is stabilized but requires significant lifestyle changes to restore long-term vitality.

2. Key Vital Signs

• Pulse (Profitability): Erratic and dangerously low. The company suffered a pre-tax loss of £11.7 million in FY2025, a dramatic plunge from a modest £443,309 profit in FY2024. The gross profit also contracted from £23.7 million to £18.8 million, indicating that the core revenue stream is shrinking.
• Blood Pressure (Net Assets/Equity):Severely depleted. Net assets dropped from a healthy £11.9 million in FY2024 to roughly £3 million in FY2025. This represents a 75% hemorrhage of the company's underlying equity value in just 12 months.
• Cholesterol (Total Liabilities):Dangerously high and accumulating. Total liabilities have more than doubled, jumping from £15.6 million to just over £33 million. This heavy debt burden restricts the company's financial circulation and increases liquidity risk.
• Immune System (Liquidity & Cash):Historically weak. Looking back at previous years (e.g., £121k-£293k cash between 2018-2021), the company has typically run with very thin cash reserves. It relies heavily on the broader group's immune system—specifically intercompany receivables—to fend off liquidity viruses.
• Life Support (Post-Balance Sheet Event):Active and essential. In June 2025, the parent company injected £10 million in exchange for 10 million £1 shares. This capital infusion is the only factor preventing the patient from slipping into a state of technical insolvency.

3. Diagnosis

Acute Operational Hemorrhage with Group-Dependent Stabilization

The FY2025 financials reveal a business that suffered a severe shock, which the directors attribute to a "general decline in European energy consumption." This macroeconomic illness caused the company's operating costs and provisions to far outpace its revenues, resulting in an £11 million operational loss.

However, this is not a standard standalone patient; it is a vital organ within a larger corporate body (the CFP Energy Group). The company's trade receivables are almost entirely intercompany, meaning its "customers" are its sister firms. When the patient bleeds, the parent body steps in. The £10 million capital injection post-year-end acts as a necessary blood transfusion, replacing the equity that was lost and ensuring the company's net assets remain in positive territory. The auditors have confirmed that the going concern basis is appropriate, but this is entirely predicated on the group's continued willingness and financial ability to provide life support.

4. Recommendations

To restore the company to robust financial health and reduce its dependency on parental life support, the following treatments are prescribed:

• Staunch the Bleeding (Cost Control & Margin Recovery): With gross profits falling, the company must urgently review its operational overhead. If the European energy market remains suppressed, the cost structure must be resized to match the lower revenue reality.
• Improve Cardiovascular Health (Cash Flow Diversification): The company is heavily reliant on intercompany flows. While low credit risk exists within the group, this creates a contagion risk—if the parent catches a cold, this subsidiary gets pneumonia. The business should seek to diversify its external client base to generate independent, third-party cash flows.
• Monitor the Group Immune System: Management must maintain active representation in the group's decision-making body (as noted in their risk report) to ensure they have early warning of any group-wide liquidity crunches that could cut off their life support.
• Build Financial Reserves: Once stabilized by the recent £10 million injection, profits should be retained within the business to build a cash buffer, rather than being distributed as dividends, ensuring the company can weather future macroeconomic shocks independently.